Scientists claimed that attitude toward remission induction (RI) for elderly patients with acute myeloid leukemia (AML) influenced survival

09-07-2006

According to recent research from Sweden, "Combination chemotherapy may induce remission from AML, but validated criteria for treatment of elderly are lacking. The RI rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the 6 health care regions, but the consequences of different management are unknown."

"The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries. Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region (range 36-76%) and the 2-year overall survival, with no censored observations (6-21%) (chi2=11.3, p<.001; r2=.86, p<.02, nonparametric)," explained G. Juliusson and colleagues, Lund University.

"A 1-month landmark analysis showed significantly better survival in regions with higher RI rates (p=.003). Differences could not be explained by demographics, and was found in both de novo and secondary leukemias. The 5-year survival of the overall population aged 70-79 years was similar between the regions."

The researchers concluded, "Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction."

Juliusson and colleagues published their study in Leukemia (Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia, 2006;20(1):42-47).

For additional information, contact G. Juliusson, Lund University, Stem Cell Center, BMC B10, SE-22185 Lund, Sweden.

Keywords: Lund, Sweden, Acute Myeloid Leukemia, Chemotherapy, Elderly, Epidemiology, Geriatrics, Oncology, Palliation, Population Based, Remission Induction, Attitude, Cancer Survival.

This article was prepared by Anti-Infectives Week editors from staff and other reports. Copyright 2006, Anti-Infectives Week via NewsRx.com.



Related Diseases: Acute Myeloid Leukemia (AML)
Related Glossary Terms: AML
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response Criteria to Advance to Full Enrollment
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Acute Myeloid Leukemia (AML)
EpiCept Receives Ceplene(R) Marketing Approval in Europe
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
New leukemia signal could point way to better treatment, Stanford researchers find
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Phase III Study of Rituxan in Leukemia Meets its Goal
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Chronic Myeloid Leukemia (CML)
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Hodgkin Lymphoma
Hodgkin lymphoma -- new characteristics discovered
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
September Is National Leukemia and Lymphoma Awareness Month
Nerve cancer mutations found
Multiple Myeloma
Thalomid® in Induction Improves Progression-free Survival in Elderly with Myeloma
The IMF says journal editorial documents dramatic increase in survival since the 1980s
FDA Approves Vidaza Label Expansion
Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
B-MS boosts biologics pipeline with PDL BioPharma deal
Myelodysplastic Syndrome (MDS)
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
FDA Approves Vidaza Label Expansion
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Non-Hodgkin Lymphoma (NHL)
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
September Is National Leukemia and Lymphoma Awareness Month
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer